Amgen announces termination of all Amgen-sponsored clinical studies of Rilotumumab
Amgen announced termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 and RILOMET-2 studies. Amgen's decision is based on a planned safety review by the RILOMET-1 IDMC. November 24, 2014